Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers Clinical Trial

Official title:

Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in Japan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04498832
• Other study ID #: EFC15150
• Secondary ID: U1111-1225-1085Q
• Status: Completed
• Phase: Phase 3
• Start date: October 21, 2020
• Est. completion date: January 14, 2021

Study information

• Verified date: September 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition [HAI] geometric mean titers [GMTs] and seroconversion rates) that was superior to responses induced by QIV-SD for the 4 virus strains at 28 days post-vaccination in all participants.

Secondary Objective:

• To describe the immune response induced by QIV-HD and QIV-SD by HAI measurement method in all participants.

• To describe the safety profile of all participants in each study group.

Description:

Study duration per participant was approximately 28 days including: 1 day of screening and vaccination, a safety follow-up telephone call and an end of study visit approximately at Day 8 and 28 after vaccination, respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2100
• Est. completion date: January 14, 2021
• Est. primary completion date: January 14, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion criteria :

• Aged greater than or equal to (>=) 60 years on the day of inclusion.

• Able to attend all scheduled visits and complied with all study procedures.

Exclusion criteria:

• Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

• Receipt of any vaccination with live vaccines within the past 27 days preceding the study vaccination or any vaccination with inactivated vaccines within the past 6 days preceding the study vaccination, or planned receipt of any vaccine prior to Visit 02.

• Previous vaccination against influenza (in the preceding 6 months) with either the study vaccine or another vaccine.

• Receipt of immune globulins, blood or blood-derived products in the past 3 months.

• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).

• Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the study or to a vaccine containing any of the same substances.

• Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on Investigator's judgment.

• Alcohol or substance abuse that, in the opinion of the Investigator might interfere with the study conduct or completion.

• Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with study conduct or completion.

• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e.,parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

• Personal or family history of Guillain-Barré syndrome.

• Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy and participants who have a history of neoplastic disease and have been disease free for >=5 years).

• Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature >=37.5 degree Celsius). A prospective participant was not be included in the study until the condition had resolved or the febrile event had subsided.

• History of convulsions.

• Any condition that in the opinion of the Investigator could interfere with the evaluation of the vaccine.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Healthy Volunteers
• Influenza, Human

Intervention

Biological:
• High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
• Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC

Locations

Country	Name	City	State
Japan	Investigational Site Number 3920005	Fukuoka-Shi
Japan	Investigational Site Number 3920004	Koganei-Shi
Japan	Investigational Site Number 3920006	Kumamoto-Shi
Japan	Investigational Site Number 3920001	Osaka-Shi
Japan	Investigational Site Number 3920003	Shinjuku-Ku
Japan	Investigational Site Number 3920008	Shinjuku-Ku
Japan	Investigational Site Number 3920009	Shinjuku-Ku
Japan	Investigational Site Number 3920002	Suita-Shi
Japan	Investigational Site Number 3920007	Toshima-Ku
Japan	Investigational Site Number 3920010	Yokohama-Shi

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Sanchez L, Nakama T, Nagai H, Matsuoka O, Inoue S, Inoue T, Shrestha A, Pandey A, Chang LJ, De Bruijn I; QHD00010 Study Group. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial. Vaccine. 2023 Apr 6;41(15):2553-2561. doi: 10.1016/j.vaccine.2023.02.071. Epub 2023 Mar 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28	GMTs of anti-influenza antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2-like, B/Victoria-like, and B/Yamagata. Titers were expressed in terms of 1/dilution.	Day 28 (post-vaccination)
Primary	Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority Analysis	Anti-influenza antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2-like, B/Victoria-like, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (<) 10 (1/dilution) and a post-vaccination titer >=40 (1/dilution) or a pre-vaccination titer >=10 (1/dilution) and a >= four-fold increase in post-vaccination titer at Day 28.	Day 28 (post-vaccination)
Secondary	GMTs of Influenza Vaccine Antibodies at Day 0 and Day 28	GMTs of anti-influenza antibodies were measured using HAI assay for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. Titers were expressed in terms of 1/dilution.	Day 0 (pre-vaccination) and Day 28 (post-vaccination)
Secondary	Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine Antibodies	GMTs of anti-influenza antibodies were measured using HAI assay for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 28) and pre-vaccination (on Day 0).	Day 0 (pre-vaccination), Day 28 (post-vaccination)
Secondary	Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens	Anti-influenza antibodies were measured by HAI assay for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer <10 (1/dilution) and a post-vaccination titer >=40 (1/dilution) or a pre-vaccination titer >=10 (1/dilution) and a >= four-fold increase in post-vaccination titer at Day 28.	Day 28 (post-vaccination)
Secondary	Percentage of Participants With HAI Titers >=40 (1/Dilution) Against Influenza Antigens	Anti-influenza antibodies were measured using HAI assay method for 6 influenza virus strains: A/H1N1, A/H3N2, A/H3N2-like, B/Victoria, B/Victoria-like, and B/Yamagata. Percentage of participants with HAI titers >=40 (1/dilution) is reported in the outcome measure.	Day 0 (pre-vaccination), Day 28 (post-vaccination)
Secondary	Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)	An AE was any untoward medical occurrence in a patient or in a clinical investigation participant administered a medicinal product and which did not necessarily have a casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRB.	Within 30 minutes post-vaccination
Secondary	Number of Participants Reporting Solicited Injection Site and Systemic Reactions	A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the product administered. Solicited injection site reactions included injection site pain, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Solicited systemic reactions included fever, headache, malaise, myalgia and shivering.	Within 7 days post-vaccination
Secondary	Number of Participants Reporting Unsolicited Adverse Events (AEs)	An AE was any untoward medical occurrence in a patient or in a clinical investigation participant administered a medicinal product and which did not necessarily have a casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination.	Within 28 days post-vaccination
Secondary	Number of Participants Reporting Serious Adverse Events (SAEs)	A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.	From Day 0 up to Day 28 post-vaccination